INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.68 USD | +0.92% |
|
-.--% | -5.79% |
Chart calendar Innovent Biologics, Inc.
f2fd2f7.RqxjdDSulCAT_GjhvuEQLuGseETEhqHWxu89B3x9xhs.dsMqMQXWxFdWqwWwiNInbJnJLi2X7vvklbtQWAlPjlEs5jlZfJvBVneeCw~8c6c375fe3cbcd117fa4f0d8912b4fb0
Upcoming events on Innovent Biologics, Inc.
Past events on Innovent Biologics, Inc.
| 2024-06-23 01:30 pm | American Diabetes Association Scientific Symposium - Abstract No : 1856-LB |
| 2024-06-20 | American Diabetes Association Scientific Symposium - Abstract No : 1857-LB |
| 2024-06-20 | American Diabetes Association Scientific Symposium - Abstract No : 1866-LB |
| 2024-06-01 05:30 pm | American Society of Clinical Oncology Meeting - Abstract No : #8520 |
| 2024-05-30 | American Society of Clinical Oncology Meeting |
| 2024-04-09 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: 5295 |
| 2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: 2718 |
| 2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: LB056 |
| 2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: LB055 |
| 2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: LB057 |
| 2024-03-19 | Q4 2023 Earnings Release |
| 2023-11-30 | European Society for Medical Oncology Asia Congress - Abstract No #: 106P |
| 2023-11-30 | European Society for Medical Oncology Asia Congress - Abstract No #: LBA12 |
| 2023-09-28 05:30 am | International Myeloma Society Meeting - Abstract No:P-290 |
| 2023-09-28 05:30 am | International Myeloma Society Meeting - Abstract No:P-288 |
| 2023-09-12 | Morgan Stanley Global Healthcare Conference |
| 2023-08-23 07:14 am | Q2 2023 Earnings Release |
| 2023-06-11 05:30 am | European Hematology Association Hybrid Congress - Abstract Number : S216 |
| 2023-06-07 | European Hematology Association Hybrid Congress - Abstract Number : P1406 |
| 2023-06-07 | European Hematology Association Hybrid Congress - Abstract Number : P1099 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 1 048 845 24.03% | 3 844 3 237 18.74% | 4 270 4 122 3.59% | 4 556 4 802 -5.12% | 6 206 5 968 3.99% | 7 630 |
|
EBITDA Million CNY | Released Forecast Spread | -1 638 -1 410 -16.21% | -242 -781 68.95% | -3 045 -1 820 -67.27% | -2 747 -2 505 -9.64% | -600 -990 39.41% | -533 |
|
EBIT Million CNY | Released Forecast Spread | -1 676 -1 474 -13.66% | -310 -820 62.13% | -3 113 -1 990 -56.43% | -3 066 -2 839 -8% | -1 679 -1 494 -12.42% | -925 |
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | -1 720 -1 556 -10.51% | -859 -733 -17.19% | -3 051 -1 893 -61.17% | -2 170 -2 620 17.16% | -1 144 -1 136 -0.77% | -824 |
|
Net income Million CNY | Released Forecast Spread | -1 720 -1 513 -13.69% | -998 -737 -35.51% | -3 138 -1 884 -66.52% | -2 179 -2 644 17.58% | -1 028 -1 197 14.16% | -846 |
|
EPS CNY | Released Forecast Spread | -1,46 -1,21 -20.33% | -0,74 -0,53 -39.41% | -2,16 -1,32 -63.14% | -1,46 -1,74 16.04% | -0,66 -0,75 12.3% | -0,53 |
| Announcement Date | 30/03/20 | 29/03/21 | 29/03/22 | 28/03/23 | 20/03/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q4 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 702 548 28.01% | 984 1 267 -22.35% | 2 860 2 828 1.1% | 1 942 1 992 -2.53% | 2 328 2 039 14.2% | 2 240 2 103 6.53% | 400 | 2 317 2 113 9.62% | 2 702 2 572 5.02% | 3 505 3 419 2.51% | 3 728 | 4 119 |
|
EBIT Million CNY | Released Forecast Spread | -1 148 -483 -137.93% | -1 960 -1 494 -31.19% | -1 212 -1 204 -0.69% | -1 617 -1 715 5.7% | -719 -1 124 36.03% | -960 -897 -7.06% | -697 | -1 025 | ||||
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | -1 876 -969 -93.59% | -999 -1 079 7.42% | -1 172 -1 529 23.38% | -256 -955 73.18% | -888 -736 -20.69% | |||||||
|
Net income Million CNY | Released Forecast Spread | -1 963 -969 -102.55% | -950 -1 120 15.1% | -1 229 -1 595 22.96% | -139 -887 84.3% | -889 -885 -0.43% | |||||||
|
EPS CNY | Released Forecast Spread | -0,84 | -0,46 | -0,28 0,39 -171.79% | -0,81 -0,24 -237.5% | -1,35 -0,91 -48.35% | -0,65 -1,02 36.27% | -0,81 -1,11 26.7% | -0,09 -0,70 87.05% | -0,57 -0,60 5% | -0,30 | -0,51 | |
| Announcement Date | 30/03/20 | 26/08/20 | 29/03/21 | 25/08/21 | 29/03/22 | 25/08/22 | - | 28/03/23 | 23/08/23 | 20/03/24 | - | - |
| 2024-07-15 | SWEDISH ORPHAN BIOVITRUM AB: Q2 2024 Earnings Release |
| 2024-07-23 02:00 am | BIOGAIA AB: Q2 2024 Earnings Release |
| 2024-07-23 | SAMSUNG BIOLOGICS CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | PHARMA MAR, S.A.: Q2 2024 Earnings Release (Projected) |
| 2024-07-25 01:00 am | UCB: Q2 2024 Earnings Release |
| 2024-07-25 | SK BIOSCIENCE CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | BIOMARIN PHARMACEUTICAL INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | GRIFOLS, S.A.: Q2 2024 Earnings Release |
| 2024-07-29 | BIOTEST AG: Q2 2024 Earnings Release |
| 2024-07-30 07:00 am | INCYTE CORPORATION: Q2 2024 Earnings Release |
Past sector events for Innovent Biologics, Inc.
| 2024-07-11 06:30 am | KALVISTA PHARMACEUTICALS, INC.: Q4 2024 Earnings Release |
| 2024-07-11 02:00 am | BONESUPPORT HOLDING AB: Q2 2024 Earnings Release |
| 2024-05-23 05:43 am | CONCORD BIOTECH LIMITED: Q4 2024 Earnings Release |
| 2024-05-15 | MEDY-TOX INC.: Q1 2024 Earnings Release |
| 2024-05-14 11:35 am | GRIFOLS, S.A.: Q1 2024 Earnings Release |
| 2024-05-13 | NATURECELL CO.,LTD.: Q1 2024 Earnings Release |
| 2024-05-09 | PHARMARESEARCH CO., LTD.: Q1 2024 Earnings Release |
| 2024-05-09 04:05 pm | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 2024-05-09 04:05 pm | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release |
| 2024-05-09 02:30 am | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
- IVBIY Stock
- Calendar Innovent Biologics, Inc.
